On June 30, 2026, Ron Bentsur, who serves as both Chairman and Chief Executive Officer of Nuvectis Pharma, Inc. (NASDAQ:NVCT), executed a purchase of 12,500 shares of the company's common stock. The transaction was completed at a price of $20 per share, resulting in a total investment of $250,000. This acquisition takes place against a backdrop of recent corporate developments that have significantly influenced the stock's trading dynamics.
The timing of Bentsur's purchase aligns closely with a public offering that Nuvectis Pharma formally announced on June 29, 2026. This offering was priced at $20 per share, involving the sale of 5,000,000 shares of common stock. To support potential demand, the company has granted underwriters a 30-day option to purchase up to an additional 750,000 shares. Following the announcement of this $100 million public offering, Nuvectis Pharma's stock experienced a notable decline. The offering price represented a substantial discount to the previous market price, which contributed to the sharp drop in the stock's value. As of the latest data, the stock trades at $19.75, slightly below Bentsur's purchase price, after declining nearly 25% over the past week.
Following this direct acquisition, Bentsur's total holdings in Nuvectis Pharma's common stock amount to 3,688,424 shares. This figure includes shares of restricted common stock and reflects his significant stake as a director and a ten percent owner of the company.
In other recent developments, H.C. Wainwright raised its price target for Nuvectis Pharma to $39, an increase from its previous target of $13, while maintaining a Buy rating. The firm based this adjustment on the inclusion of NXP100 and NXP200 in its valuation model, citing positive pivotal data from China. These developments reflect Nuvectis Pharma's ongoing efforts to expand its pipeline and secure additional funding.
According to InvestingPro analysis, the stock appears overvalued at current levels, with 12 additional ProTips available to subscribers. The company's stock data shows a real-time price of $19.14, reflecting a change of +0.75 (+4.08%) as of 14:07:08 USD. The stock has been tracked across multiple timeframes, including 1D, 1W, 1M, 6M, 1Y, 5Y, and Max, with data points recorded on 30/06 and 01/07, showing prices ranging from 16 to 20.
ProPicks AI evaluates NVCT alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%).